This inventor holds 1 USPTO granted patent. Top assignee: Glaxosmithkline Intellectual Property Development Limited. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: William E. Fieles: Innovator in Multiple Myeloma Prognosis
Introduction
William E. Fieles is a notable inventor based in Collegeville, PA (US). He has made significant contributions to the field of medical research, particularly in the prognosis and treatment of multiple myeloma. His innovative work has led to the development of methods that enhance patient care and treatment outcomes.
Latest Patents
William E. Fieles holds a patent for a prognostic method that determines the prognosis of multiple myeloma in patients. This method involves measuring the expression of BCMA in a sample. Additionally, he has developed methods for treating multiple myeloma by administering an effective amount of an antigen-binding protein that binds to BCMA. His patent also includes kits designed for measuring BCMA expression in samples.
Career Highlights
Fieles is associated with GlaxoSmithKline Intellectual Property Development Limited, where he applies his expertise in medical innovation. His work has been instrumental in advancing the understanding and treatment of multiple myeloma, a complex and challenging disease.
Collaborations
Throughout his career, William E. Fieles has collaborated with esteemed colleagues, including Laura M. Seestaller-Wehr and James Tunstead. These partnerships have fostered a collaborative environment that promotes innovation and research excellence.
Conclusion
William E. Fieles is a distinguished inventor whose work in the field of multiple myeloma has made a significant impact on patient prognosis and treatment. His contributions continue to shape the future of medical research and innovation.